(Q40905445)

24 September 2017

1 reference

title

Pharmacokinetic optimisation of the treatment of deep vein thrombosis (English)

1 reference

24 September 2017

0 references

1 reference

Iorio A

1

1 reference

24 September 2017

Agnelli G

series ordinal

2

1 reference

24 September 2017

publication date

1 February 1997

1 reference

Clinical Pharmacokinetics

24 September 2017

published in

1 reference

24 September 2017

volume

32

1 reference

24 September 2017

issue

2

1 reference

24 September 2017

page(s)

145-172

1 reference

Streptokinase treatment of deep venous thrombosis and the postthrombotic syndrome. Follow-up evaluation of venous function

24 September 2017

cites work

1 reference

12 December 2020

Determinants of the anticoagulant effect of heparin in vitro

1 reference

12 December 2020

Comparative human pharmacology of low molecular weight heparins

1 reference

12 December 2020

Heparin kinetics: variables related to disposition and dosage

1 reference

12 December 2020

A computer program for long term anticoagulation control

1 reference

12 December 2020

Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial

1 reference

12 December 2020

Oral anticoagulant drugs: pharmacokinetic aspects

1 reference

12 December 2020

Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behaviour

1 reference

12 December 2020

Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine.

1 reference

12 December 2020

Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time

1 reference

12 December 2020

Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardization

1 reference

12 December 2020

Neutralisation of heparan sulphate and low molecular weight heparin by protamine.

1 reference

12 December 2020

Multicenter evaluation of six methods for predicting warfarin maintenance-dose requirements from initial response.

1 reference

12 December 2020

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models

1 reference

12 December 2020

Pharmacokinetics of low molecular weight heparins

1 reference

12 December 2020

Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association

1 reference

12 December 2020

A Brief Account of a Disease in Cattle Simulating Hemorrhagic Septicaemia due to Feeding Sweet Clover.

1 reference

12 December 2020

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

1 reference

12 December 2020

Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

1 reference

12 December 2020

The stereoselective interaction of warfarin and metronidazole in man

1 reference

12 December 2020

Aging and warfarin therapy

1 reference

12 December 2020

Warfarin-induced skin necrosis: report of four cases.

1 reference

12 December 2020

Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism

1 reference

12 December 2020

Pharmacokinetic implications of stereoselective changes in plasma-protein binding: warfarin/sulfinpyrazone

1 reference

12 December 2020

Structure of the antithrombin-binding site in heparin

1 reference

12 December 2020

Heparin kinetics in venous thrombosis and pulmonary embolism

1 reference

12 December 2020

Warfarin dosage and vitamin K in Osmolite

1 reference

12 December 2020

Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation

1 reference

12 December 2020

Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control

1 reference

12 December 2020

Effect of heparin on prothrombin time

1 reference

12 December 2020

A simple technic for predicting daily maintenance dose of warfarin

1 reference

12 December 2020

Pharmacokinetics of intravenously and subcutaneously administered Fragmin in healthy volunteers

1 reference

12 December 2020

INFLUENCE OF FEVER UPON THE ACTION OF 3,3'-METHYLENE-BIS-(4-HYDROXYCOUMARIN) (DICUMAROL).

1 reference

12 December 2020

Predictability of Warfarin Dose Requirements: Theoretical Considerations

1 reference

12 December 2020

Vitamin K deficiency from dietary vitamin K restriction in humans

1 reference

12 December 2020

Clinical pharmacology of recombinant hirudin

1 reference

12 December 2020

Optimal Therapeutic Level of Heparin Therapy in Patients With Venous Thrombosis

1 reference

12 December 2020

Low molecular weight heparin half life is prolonged in haemodialysed patients

1 reference

12 December 2020

Bolus thrombolysis in venous thromboembolism

1 reference

12 December 2020

Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention

1 reference

12 December 2020

A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease

1 reference

12 December 2020

Hirudins: antithrombin anticoagulants

1 reference

12 December 2020

The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg.

1 reference

12 December 2020

Heparin pharmacokinetics: increased requirements in pulmonary embolism

1 reference

12 December 2020

Sequelae of venous thrombosis. Incidence in of the post-thrombosis syndrome after 5 years

1 reference

12 December 2020

Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants

1 reference

12 December 2020

Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg

1 reference

12 December 2020

Aging and the anticoagulant response to warfarin therapy

1 reference

12 December 2020

"Resistance" to warfarin due to unrecognized vitamin K supplementation.

1 reference

12 December 2020

Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis

1 reference

12 December 2020

Prospective evaluation of a flexible protocol for starting treatment with warfarin and predicting its maintenance dose

1 reference

12 December 2020

Heparin half-life and sensitivity in normal subjects and in patients affected by deep vein thrombosis.

1 reference

12 December 2020

Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders

1 reference

12 December 2020

Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis--a randomized clinical trial

1 reference

12 December 2020

Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics

1 reference

12 December 2020

Protein C and the development of skin necrosis during anticoagulant therapy

1 reference

12 December 2020

Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial

1 reference

12 December 2020

Kinetics of warfarin absorption in man

1 reference

12 December 2020

Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator. Efficacy of dosing regimes

1 reference

12 December 2020

Hereditary warfarin resistance. Investigation of a rare phenomenon.

1 reference

12 December 2020

Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations

1 reference

12 December 2020

Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients.

1 reference

12 December 2020

Heparin and the activated partial thromboplastin time--a difference between the in-vitro and in-vivo effects and implications for the therapeutic range

1 reference

12 December 2020

Age as a determinant of sensitivity to warfarin

1 reference

12 December 2020

Urokinase versus tissue plasminogen activator in pulmonary embolism

1 reference

12 December 2020

Pharmacokinetics of heparin and related polysaccharides

1 reference

12 December 2020

Accuracy of a first-order model for estimating initial heparin dosage.

1 reference

12 December 2020

Flexible induction dose regimen for warfarin and prediction of maintenance dose

1 reference

12 December 2020

Warfarin skin necrosis. The role of factor VII.

1 reference

12 December 2020

Rapid determination of maintenance heparin infusion rates with the use of non-steady-state heparin concentrations

1 reference

12 December 2020

Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis

1 reference

12 December 2020

Heparin kinetics determined by three assay methods

1 reference

12 December 2020

Adjusted-dose intravenous heparin treatment evaluation of an automated and a non automated schedule

1 reference

12 December 2020

Clinico-pharmacological studies with recombinant hirudin

1 reference

12 December 2020

The kinetics of heparin

1 reference

12 December 2020

THE BIOLOGICAL DISAPPEARANCE RATE OF PROTHROMBIN, FACTORS VII, IX AND X FROM PLASMA IN HYPOTHYROIDISM, HYPERTHYROIDISM, AND DURING FEVER

1 reference

12 December 2020

Audit of control of heparin treatment

1 reference

12 December 2020

Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis

1 reference

12 December 2020

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

12 December 2020

The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial

1 reference

12 December 2020

Interaction between warfarin and propafenone in healthy volunteer subjects

1 reference

12 December 2020

Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man

1 reference

12 December 2020

The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin

1 reference

12 December 2020

Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism

1 reference

12 December 2020

Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers

1 reference

12 December 2020

Heparin-induced thrombocytopenia, thrombosis, and hemorrhage

1 reference

12 December 2020

Heparin clearance in the newborn

1 reference

12 December 2020

The development of hirudin as an antithrombotic drug

1 reference

12 December 2020

HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED.

1 reference

12 December 2020

Interaction of chronic daily warfarin therapy and rifampin

1 reference

12 December 2020

Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration

1 reference

12 December 2020

Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).

1 reference

12 December 2020

Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.

1 reference

12 December 2020

Pharmacy-managed, weight-based heparin protocol

1 reference

12 December 2020

Heparin treatment of deep venous thrombosis in 280 patients: symptoms related to dosage

1 reference

12 December 2020

Tissue plasminogen activator promotes platelet disaggregation in plasma

1 reference

12 December 2020

Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy

1 reference

12 December 2020

Kinetics of intravenously administered heparin in normal humans

1 reference

12 December 2020

Heparin therapy adjusted for body weight

1 reference

12 December 2020

Effect of concomitantly administered drugs on the control of long term anticoagulant therapy

1 reference

12 December 2020

Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group

1 reference

12 December 2020

Pharmacokinetics of low molecular weight heparins

1 reference

12 December 2020

Pharmacokinetics and anticoagulant effect of hirudin in man.

1 reference

12 December 2020

High-Pressure Liquid Chromatographic Analysis of drugs in Biological Fluids I: Warfarin

1 reference

12 December 2020

Comparative dosage and toxicity of heparin sodium in the treatment of patients with pulmonary embolism versus deep-vein thrombosis

1 reference

12 December 2020

Managing the hemorrhagic complications of heparin therapy.

1 reference

12 December 2020

Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects

1 reference

12 December 2020

LMW heparin (anti-Xa) assays for clinical monitoring and pharmacokinetic studies on the automated coagulation laboratory (ACL)

1 reference

12 December 2020

Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service

1 reference

12 December 2020

Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis

1 reference

12 December 2020

Evaluation of a computer-assisted method for individualized anticoagulation: retrospective and prospective studies with a pharmacodynamic model

1 reference

12 December 2020

Pharmacodynamics of warfarin at steady state

1 reference

12 December 2020

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

12 December 2020

Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group

1 reference

12 December 2020

Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum).

1 reference

12 December 2020

Clinically significant hemorrhage due to warfarin-carbamazepine interaction

1 reference

12 December 2020

Comparison of two APTT methods of monitoring heparin therapy. APTT ratio and heparin response of pooled normal plasma

1 reference

12 December 2020

Warfarin-phenylbutazone interaction in man: a long term multiple dose study

1 reference

12 December 2020

The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits

1 reference

12 December 2020

Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial.

1 reference

12 December 2020

A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.

1 reference

12 December 2020

The pharmacology of recombinant hirudin, a new anticoagulant

1 reference

12 December 2020

Predicting warfarin maintenance dosage based on initial response

1 reference

12 December 2020

Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis

1 reference

12 December 2020

Absence of transplacental passage of fragmin (Kabi) during the second and the third trimesters of pregnancy

1 reference

12 December 2020

Drug interactions with coumarin anticoagulants. 2.

1 reference

12 December 2020

Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders

1 reference

12 December 2020

Pharmacokinetics of fragmin. A comparative study in the rabbit of its high and low affinity forms for antithrombin

1 reference

12 December 2020

Thrombin inhibition by covalently bound hirudin

1 reference

12 December 2020

Mechanism of the anticoagulant action of heparin

1 reference

12 December 2020

Establishing a therapeutic range for heparin therapy

1 reference

12 December 2020

Bayesian forecasting of APTT response to continuously infused heparin with and without warfarin administration

1 reference

12 December 2020

Plasma thrombin neutralization assay: pharmacokinetic applications

1 reference

12 December 2020

Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy

1 reference

12 December 2020

Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis. A prospective study

1 reference

12 December 2020

Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound

1 reference

12 December 2020

Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy

1 reference

12 December 2020

A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism

1 reference

12 December 2020

Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K--epoxide cycle

1 reference

12 December 2020

Studies on the optical enantiomorphs of warfarin in man

1 reference

12 December 2020

A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol)

1 reference

12 December 2020

Duration of anticoagulant therapy in venous thrombo--embolism

1 reference

12 December 2020

Heparin and the in-hospital management of deep venous thrombosis: cost considerations

1 reference

12 December 2020

Prediction of maintenance warfarin dosage from initial patient response

1 reference

12 December 2020

Determinants of the response to oral anticoagulant drugs in man

1 reference

12 December 2020

The discovery of dicumarol and its sequels

1 reference

12 December 2020

Altered heparin pharmacodynamics in patients with pulmonary embolism

1 reference

12 December 2020

Interaction of secobarbital with warfarin pseudoracemates

1 reference

12 December 2020

Physician-guided treatment compared with a heparin protocol for deep vein thrombosis

1 reference

12 December 2020

Population pharmacokinetics of racemic warfarin in adult patients

1 reference

12 December 2020

Relationship between the kinetics of the anticoagulant effects of racemic warfarin and its individual enantiomers in man

1 reference

12 December 2020

Vitamin K and the oral anticoagulant drugs

1 reference

12 December 2020

Rationale for bolus t-PA therapy to improve efficacy and safety

1 reference

12 December 2020

Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement

1 reference

12 December 2020

Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins

1 reference

12 December 2020

Evaluation of three dosage-prediction methods for initial in-hospital stabilization of warfarin therapy

1 reference

12 December 2020

Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders

1 reference

12 December 2020

Studies on the frequency of heparin-associated thrombocytopenia

1 reference

12 December 2020

Heparin half-life in normal and impaired renal function

1 reference

12 December 2020

A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis

1 reference

12 December 2020

Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases.

1 reference

12 December 2020

Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing.

1 reference

12 December 2020

Recurrence of venous thromboembolism

1 reference

12 December 2020

Reocclusion after thrombolysis: a problem solved by hirudin?

1 reference

12 December 2020

Pharmacokinetic modeling of heparin and its clinical implications

1 reference

12 December 2020

A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan

1 reference

12 December 2020

Intersubject variability in the anticoagulant response to heparin in vitro

1 reference

12 December 2020

Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis

1 reference

12 December 2020

Heparin elimination in uraemic patients on Haemodialysis

1 reference

12 December 2020

Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man.

1 reference

12 December 2020

One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis.

1 reference

12 December 2020

The warfarin-sulfinpyrazone interaction: stereochemical considerations

1 reference

12 December 2020

Warfarin-griseofulvin interaction

1 reference

12 December 2020

Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis

1 reference

12 December 2020

Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis

1 reference

12 December 2020

Historical data regarding the experiences with coumarin anticoagulants at the University of Wisconsin Medical School

1 reference

12 December 2020

Effect of warfarin on the activated partial thromboplastin time

1 reference

12 December 2020

Computer-aided long-term anticoagulation therapy

1 reference

12 December 2020

Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing

1 reference

12 December 2020

Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure

1 reference

12 December 2020

Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin

1 reference

12 December 2020

Predictability of the warfarin maintenance dosage based on the initial response

1 reference

12 December 2020

Appropriate use of heparin. Empiric vs nomogram-based dosing

1 reference

12 December 2020

Heparin-induced thrombocytopenia in patients with cerebrovascular ischemic disease

1 reference

12 December 2020

Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits

1 reference

12 December 2020

Effect of using warfarin plasma concentrations in Bayesian forecasting of prothrombin-time response

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers

1 reference

12 December 2020

Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature

1 reference

12 December 2020

The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer

1 reference

12 December 2020

Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers

1 reference

12 December 2020

Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis

1 reference

12 December 2020

Drug interactions with warfarin

1 reference

12 December 2020

Pharmacology of r-hirudin in renal impairment

1 reference

12 December 2020

A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits.

1 reference

12 December 2020

The mechanism of the interaction between amiodarone and warfarin in humans

1 reference

12 December 2020

1 reference

12 December 2020

Treatment of severe venous thrombo-embolism with intravenous Hirudin (HBW 023): an open pilot study

1 reference

12 December 2020

The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits

1 reference

12 December 2020

Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial.

1 reference

12 December 2020

Calculation of heparin dosage in a morbidly obese woman

1 reference

12 December 2020

Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.

1 reference

12 December 2020

Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis

1 reference

12 December 2020

Prolonged hospitalization because of inappropriate delay of warfarin therapy in deep venous thrombosis

1 reference

12 December 2020

Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans

1 reference

12 December 2020

An objective study of alternative methods of heparin administration

1 reference

12 December 2020

Oral anticoagulant drugs

1 reference

12 December 2020

Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration

1 reference

12 December 2020

May mothers given warfarin breast-feed their infants?

1 reference

12 December 2020

The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin.

1 reference

12 December 2020

Efficacy and Toxicity of Heparin in Relation to Age and Sex

1 reference

12 December 2020

Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association

1 reference

12 December 2020

A Standard Heparin Nomogram for the Management of Heparin Therapy

1 reference

12 December 2020

Low molecular weight heparin

1 reference

12 December 2020

Coumarin necrosis associated with hereditary protein C deficiency

1 reference

12 December 2020

Heparin degradation in the endothelial cells

1 reference

12 December 2020

Digital computer-assisted warfarin therapy: Comparison of two models

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man

1 reference

12 December 2020

Is warfarin sodium contraindicated in the lactating mother?

1 reference

12 December 2020

Heparin pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor

1 reference

12 December 2020

Evaluation of a Bayesian regression program for predicting warfarin response.

1 reference

12 December 2020

Anticoagulant therapy by continuous heparinization in newborn and older infants

1 reference

12 December 2020

Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone

1 reference

12 December 2020

Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose

1 reference

12 December 2020

Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis

1 reference

12 December 2020

Physician practices in the treatment of pulmonary embolism and deep venous thrombosis

1 reference

12 December 2020

Plasma level of dextran-r-hirudin

1 reference

12 December 2020

A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis

1 reference

12 December 2020

Pharmacokinetics of a low molecular weight heparin [Fragmin] in young and elderly subjects

1 reference

12 December 2020

Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model

1 reference

12 December 2020

Heparin response and clearance in acute and chronic liver disease

1 reference

12 December 2020

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

1 reference

12 December 2020

DRUG INTERACTIONS IN MAN. I. LOWERING EFFECT OF PHENOBARBITAL ON PLASMA LEVELS OF BISHYDROXYCOUMARIN (DICUMAROL) AND DIPHENYLHYDANTOIN (DILANTIN)

1 reference

12 December 2020

Predicting patients' warfarin requirements

1 reference

12 December 2020

Guidelines to control heparin treatment

1 reference

12 December 2020

Oral anticoagulant therapy

1 reference

12 December 2020

Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis

1 reference

12 December 2020

Clinical pharmacokinetics of heparin

1 reference

12 December 2020

Short-term ultrahigh streptokinase treatment of chronic arterial occlusions and acute deep vein thromboses

1 reference

12 December 2020

Pharmacist-directed heparin therapy using a standard dosing and monitoring protocol

1 reference

12 December 2020

Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis

1 reference

12 December 2020

Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy

1 reference

12 December 2020

10.2165/00003088-199732020-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

24 September 2017

1043273085

0 references

1 reference